CD5 and diffuse large B-cell lymphoma: We previously analyzed 90 patients with DLBCL, NOS by gene expression profiling (GEP) and identified the signature genes that could divide DLBCLs into two groups: a CD5+ group and a CD5‐negative (CD5−) group 6.